Literature DB >> 33537945

Cannabis for Restless Legs Syndrome.

Imad Ghorayeb1,2,3.   

Abstract

Restless legs syndrome (RLS) is a chronic sensorimotor disorder characterized by an urge to move the legs. This urge is often accompanied by pain or other uncomfortable and unpleasant sensations, it either occurs or worsens during rest, particularly in the evening and/or at night, and temporarily improves with activity. Affecting nearly 3% of the North American and European populations in its moderate-to-severe form, RLS has a considerable negative impact on the quality of life, and sleep and is associated with significant morbidity. Although new developments have deepened our understanding of the disorder, yet, the corresponding pathophysiologic features that underlie the sensorimotor presentation are still not fully understood. Usually, symptoms respond well to dopamine agonists (DA), anticonvulsants, or opiates, used either alone or in any combination, but still, a subset of patients remains refractory to medical therapy and serious side effects such as augmentation and impulse control disorder may occur in patients with RLS under DA. Convincing treatment alternative are lacking but recently patients' spontaneous reports of a remarkable and total remission of RLS symptoms following cannabis use has been reported. The antinociceptive effect of marijuana has been documented in many painful neurological conditions and the potential benefit of cannabis use in patients with refractory RLS should, therefore, be questioned by robust clinical trials. Here, we review basic knowledge of RLS and the putative mechanisms by which cannabis may exert its analgesic effects.

Entities:  

Keywords:  Cannabis; Restless legs syndrome; Treatment

Mesh:

Substances:

Year:  2021        PMID: 33537945     DOI: 10.1007/978-3-030-61663-2_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  68 in total

1.  Restless legs syndrome prevalence and impact: REST general population study.

Authors:  Richard P Allen; Arthur S Walters; Jacques Montplaisir; Wayne Hening; Andrew Myers; Timothy J Bell; Luigi Ferini-Strambi
Journal:  Arch Intern Med       Date:  2005-06-13

2.  Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance.

Authors:  Richard P Allen; Daniel L Picchietti; Diego Garcia-Borreguero; William G Ondo; Arthur S Walters; John W Winkelman; Marco Zucconi; Raffaele Ferri; Claudia Trenkwalder; Hochang B Lee
Journal:  Sleep Med       Date:  2014-05-17       Impact factor: 3.492

3.  Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample.

Authors:  Richard P Allen; William G Ondo; Eric Ball; Michael O Calloway; Ranjani Manjunath; Rachel L Higbie; Mechele R Lee; Paul A Nisbet
Journal:  Sleep Med       Date:  2011-04-13       Impact factor: 3.492

4.  Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report.

Authors:  Richard P Allen; Daniel L Picchietti; Michael Auerbach; Yong Won Cho; James R Connor; Christopher J Earley; Diego Garcia-Borreguero; Suresh Kotagal; Mauro Manconi; William Ondo; Jan Ulfberg; John W Winkelman
Journal:  Sleep Med       Date:  2017-11-24       Impact factor: 3.492

5.  MRI measurement of brain iron in patients with restless legs syndrome.

Authors:  R P Allen; P B Barker; F W Wehrl; F Wehrl; H K Song; C J Earley
Journal:  Neurology       Date:  2001-01-23       Impact factor: 9.910

6.  Autonomic innervation of receptors and muscle fibres in cat skeletal muscle.

Authors:  D Barker; M Saito
Journal:  Proc R Soc Lond B Biol Sci       Date:  1981-07-14

Review 7.  The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report.

Authors:  Donald I Abrams
Journal:  Eur J Intern Med       Date:  2018-01-09       Impact factor: 4.487

8.  Treatment of restless legs syndrome with levodopa plus benserazide.

Authors:  S Akpinar
Journal:  Arch Neurol       Date:  1982-11

9.  Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis.

Authors:  Richard P Allen; James R Connor; Keith Hyland; Christopher J Earley
Journal:  Sleep Med       Date:  2008-01-28       Impact factor: 3.492

10.  Nutritional iron and dopamine binding sites in the rat brain.

Authors:  R Ashkenazi; D Ben-Shachar; M B Youdim
Journal:  Pharmacol Biochem Behav       Date:  1982       Impact factor: 3.533

View more
  1 in total

Review 1.  Cannabinoids for Symptom Management in Patients with Kidney Failure: A Narrative Review.

Authors:  Hayley Worth; Daniel V O'Hara; Neeru Agarwal; David Collister; Frank Brennan; Brendan Smyth
Journal:  Clin J Am Soc Nephrol       Date:  2022-01-05       Impact factor: 10.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.